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Abstract
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The objective of this study was to determine whether the interaction between type of serious
mental illness (SMI) and pre-treatment drinking severity, assessed by ethyl glucuronide (EtG),
predicts EtG-positive urine samples submitted during treatment in outpatients with co-occurring
alcohol dependence and SMI. Seventy-nine participants were randomized to treatment-as-usual or
treatment-as-usual and contingency management (CM) targeting alcohol abstinence. Generalized
estimating equations were used to assess the interaction of pre-treatment drinking (heavy drinking
or light drinking) and SMI diagnosis (major depression, bipolar, or schizophrenia-spectrum
disorders) across a 12-week treatment period. In the overall sample, the interaction of drinking
severity and SMI diagnosis (p = 0.006) was associated with alcohol abstinence. Exploratory
analyses of the interaction term among participants randomized to CM (n = 40; p = 0.008) were
associated with alcohol abstinence during CM. Type of SMI diagnosis was associated with
treatment outcomes in individuals who engaged in heavy drinking, but not light drinking, prior to
treatment.
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Nearly 50% of people with serious mental illness (SMI), defined as schizophrenia-spectrum,
bipolar, and recurrent major depressive disorders experience a co-occurring alcohol use
disorder in their lifetimes (Davis et al. 2008; Koskinen et al. 2009; Regier et al. 1990). These
individuals have high levels of psychotic symptoms, inpatient psychiatric and emergency
care utilization, treatment dropout, and suicide as a result of co-occurring disorders (Buckley
and Brown 2006; Gonzalez et al. 2007; Kreyenbuhl et al. 2009; McGovern et al. 2007).
Various behavioral treatments (e.g., cognitive behavior therapy, contingency management
(CM)) or a combination of treatments are associated with reductions in alcohol and drug use
in adults with SMI (Barrowclough et al. 2010; Bellack et al. 2006; Bradizza et al. 2014;
McDonell et al. 2013, 2017). However, less is known about the predictors of treatment
outcomes in those receiving co-occurring disorder treatment for alcohol and schizophreniaspectrum, bipolar I and II, or major depressive disorders.
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CM provides reinforcers for targeted behavior, typically abstinence verified by urine drug
tests, and is associated with decreased substance use, psychiatric symptoms, and
hospitalization in outpatients diagnosed with an SMI (Bellack et al. 2006; McDonell et al.
2013, 2017). In two randomized trials of CM, one targeting stimulant drug use and the other
alcohol use, pre-treatment alcohol or drug positive urine tests were associated with poor
treatment outcomes (Angelo et al. 2013). In a trial of CM targeting alcohol use, participants
submitted urine samples that were tested for ethyl glucuronide (EtG), an alcohol metabolite,
for 4 weeks before randomization. Participants who had pre-randomization EtG levels
consistent with regular heavy drinking (EtG > 499 ng/mL) attained a period of alcohol
abstinence during CM that was 2.5 times shorter than those who were light drinkers
(McDonell et al. 2017).
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Findings have been inconsistent in terms of the association between type of SMI diagnosis
and treatment outcomes. We observed that higher levels of psychological distress (e.g.,
anxiety, stress), rather than type of SMI diagnosis was a predictor of abstinence among
adults with SMI receiving CM for stimulant use (Angelo et al. 2013). In non-SMI
populations, depressive symptoms were associated with poorer treatment outcomes in CM
for cocaine dependence (García-Fernández et al. 2013). Another study found that the
diagnosis of major depression or antisocial personality disorder predicted poorer treatment
outcomes at 1-year follow-up among adults in drug treatment (Compton et al. 2003).
Pre-treatment substance use and psychiatric symptom severity have been independently
associated with treatment outcomes in CM, and initial evidence suggests that type of
psychiatric diagnosis is associated with addiction treatment outcomes. However, to our
knowledge no research has tested whether the interaction of these variables predicts
addiction treatment outcomes. Understanding how the heterogeneity in alcohol use and SMI
diagnosis interact could provide clinicians with valuable information to improve and tailor
treatment for subgroups of adults with co-occurring disorders. The purpose of this study was
Int J Ment Health Addict. Author manuscript; available in PMC 2018 July 02.
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to explore whether the interaction of pre-treatment drinking severity (heavy versus light
drinking) assessed by EtG and type of SMI diagnosis (major depression, bipolar, or
schizophrenia-spectrum disorders) predicted alcohol abstinence in the overall sample of
adults with SMI and AUDs receiving treatment-as-usual (TAU; N = 79), as well as in those
randomized to CM (n = 40).

Methods
Sample
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Participants were recruited from multiple community mental health and substance use
treatment agencies in Washington State. Seventy-nine adults who met criteria for the
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision
(DSM-IV-TR) diagnoses of alcohol dependence and co-occurring schizophrenia-spectrum (n
= 29), bipolar (n = 24), or major depressive disorders (n = 27), assessed by the Mini
International Neuro-psychiatric Interview (M.I.N.I) were enrolled (Sheehan et al. 1998).
Other inclusion criteria (detailed in McDonell et al. 2017) included alcohol use on 5 out of
the prior 30 days. The mean age of participants was 45.38 (SD = 10.20) years, and 65% (n =
51) were male, 53% (n = 42) were white, 29% (n = 23) black, 15% (n = 12) other, and 3% (n
= 2) of unknown racial identify. Fifty-three percent (n = 42) were heavy drinkers as defined
by pre-treatment EtG levels. Participants provided written informed consent and the study
was approved by the University of Washington’s Institutional Review Board.
Study Design and Procedures
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McDonell et al. (2017) conducted a 16-week randomized controlled trial of CM for alcohol
dependence (clinicaltrials.govidentifier:NCT01567943). Participants engaged in a 4-week
induction period (weeks 1–4), developed to increase study retention after randomization that
included treatment-as-usual(TAU). Participants received reinforcers (prize draws) three
times a week for submitting urine samples regardless of whether it was positive or negative
and for alcohol and provided self-reported data on alcohol use. After the induction period,
participants who provided at least one EtG-positive urine sample continued to receive TAU
and were randomized (weeks 5–16) to either the CM (n = 40) or non-contingent (NC; n =
39) control conditions for the 12-week treatment period. Following the treatment period,
participants completed a 3-month follow-up (weeks 17–28) period.
Study Interventions
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TAU occurred at three sites of a large urban community mental health center in Seattle, WA.
Addiction treatment consisted of group counseling sessions 2–4 times a week. Additional
services were provided by site staff, including individual addiction counseling, case
management, medication management, and housing support.
The variable magnitude of reinforcement procedure was utilized and involved “prize draws”
from a bucket that contained tokens that reflected various values. Fifty percent of the tokens
read “good job,” 41.8% read “small” ($1 value), 8.0% read “large” ($20 value), and 0.2%
read “jumbo” ($80 value). NC control participants earned at least three prize draws per urine
sample submitted regardless of results, and CM participants earned prize draws for each
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EtG-negative sample submitted and an additional draw for each consecutive week of
abstinence. EtG-positive urine tests resulted in no prize draws and a reset to three prize
draws the next time an EtG-negative sample was provided. CM participants also received
gift cards if they attended some ($5) or all ($10) of their addiction treatment groups each
week. NC control participants received the average value of gift cards received by the CM
condition regardless of addiction treatment group attendance.
Measures
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Participants completed an enrollment interview that included the M.I.N.I., which was used to
determine type of SMI diagnosis and assess for alcohol dependence and drug use disorders.
M.I.N.I. major depressive episode, manic episode, psychotic disorders, and drug and alcohol
dependence/abuse diagnostic sections were administered by trained research staff. Urine
samples were collected at each study visit and assessed for EtG using Diagnostic Reagents
Incorporated EtG-immunoassay onsite with a Thermo Fisher Indiko analyzer (Fremont,
CA), with a detectable range of 0 to 2000 ng/mL. Mean EtG levels were calculated across
the 4-week induction period for each participant to determine pre-treatment drinking
severity, those with EtG >499ng/mL (i.e., heavy drinking) or EtG <500 ng/mL (i.e., light
drinking) (McDonell et al. 2015). The outcome variable was number of EtG-positive (EtG >
149 ng/mL) urine samples submitted during the 36-visit treatment period.
Data Analysis

Author Manuscript

Generalized estimating equation (GEE) analyses were used to assess the relationship
variables of interest and alcohol use during the 12-week treatment period. The first model (N
= 79) controlled for treatment condition, SMI diagnosis (schizophrenia-spectrum, bipolar,
major depressive disorders), pre-treatment drinking severity, and the interaction between
type of SMI diagnosis and pre-treatment drinking severity with the outcome being EtGpositive urine samples during treatment (1 = yes, 0 = no). The second model within the CM
condition only (n = 40) assessed whether the interaction of pre-treatment drinking severity
and SMI diagnosis was associated with EtG-positive urine samples, controlling for pretreatment drinking severity and SMI diagnosis. In both analyses, all possible pairwise
comparisons were conducted on the interaction term utilizing Bonferroni correction to avoid
inflation of the alpha rate. Odds ratios (OR) were reported, 95% confidence intervals (CI),
and significance was set at p < 0.05. Analyses were performed using IBM SPSS 24.0 and
post hoc tests were conducted in Stata 12.0 (StataCorp, College Station, TX).

Results
Author Manuscript

Across the entire sample, after controlling for treatment conditions (χ2 (1) = 7.86, p =
0.005), pre-treatment drinking severity (χ2 (1) = 38.55, p = 0.001), and SMI diagnosis (χ2
(2) = 7.64, p = 0.022), the interaction of pre-treatment drinking severity and SMI diagnosis
(χ2 (2) = 10.39, p = 0.006) was a significant predictor of submitting EtG-positive urine
samples during the treatment period.
Post hoc tests for the interaction term revealed that heavy drinkers with bipolar disorders
(OR = 0.09, 95% CI 0.04–0.22) and schizophrenia-spectrum disorders (OR = 0.25, 95% CI
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0.11–0.58) were less likely than heavy drinkers with major depression to submit EtGpositive urine samples during the treatment period. Heavy drinkers with schizophreniaspectrum disorders were 2.83 times (95% CI 1.32–6.09) more likely than heavy drinkers
with bipolar disorder to submit EtG-positive urine samples during the treatment period (see
Fig. 1). No significant differences were found among light drinkers across SMI diagnoses.
Although, among those with major depression (OR = 29.28, 95% CI 10.53–81.45) and
schizophrenia-spectrum (OR = 5.62, 95% CI 2.37–13.35) disorders, heavy drinkers were
more likely than light drinkers to submit EtG-positive samples during treatment. Differences
between heavy and light drinkers in those with bipolar were not significant.

Author Manuscript

Similar findings were observed when analyses were conducted on participants randomized
to CM only. After controlling for pre-treatment drinking severity (χ2 (1) = 23.41, p = 0.001)
and SMI diagnosis (χ2 (2) = 2.07, p = 0.36), the interaction of pre-treatment drinking
severity and SMI diagnosis (χ2 (2) = 9.72, p = 0.008) was associated with EtG-positive
urine samples during the treatment period. Bonferroni post hoc tests, conducted on the
interaction term revealed that heavy drinkers with bipolar (OR = 0.13, 95% CI 0.03–0.47)
and schizophrenia-spectrum (OR = 0.13, 95% CI 0.03–0.47) disorders were less likely than
heavy drinkers with major depression to submit EtG-positive urine samples during the
treatment period. No significant differences were found among light drinkers across SMI
diagnoses. However, among those with major depression (OR = 87.02, 95% CI 17.08–
443.23) and schizophrenia-spectrum (OR = 5.57, 95% CI 1.52–20.45) disorders, heavy
drinkers were more likely than light drinkers to submit EtG-positive samples during
treatment. Differences between heavy and light drinkers in those with bipolar were not
significant.

Author Manuscript

Discussion
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Previous findings have suggested that light drinkers relative to heavy drinkers were
significantly less likely to submit EtG-positive urine samples during the treatment period
and that psychiatric distress rather than SMI diagnosis predicted outcomes (Angelo et al.
2013; McDonell et al. 2017). Although not a CM trial, research has revealed that individuals
with a major depression diagnosis were more likely to meet criteria for alcohol dependence
compared to other psychiatric disorders(Compton et al. 2003). Contrary to previous research
that found psychiatric distress not SMI was a significant predictor of outcomes, our study
found that alcohol use during the treatment period varied by SMI diagnosis in heavy, but not
light drinkers, as seen in Fig. 1. Heavy drinkers with major depression were more likely to
submit EtG-positive urine samples during treatment compared to heavy drinkers with bipolar
and schizophrenia-spectrum disorders. Similar results were also found when analyses were
restricted to the CM condition only. In contrast, outcomes did not differ across SMI
diagnoses in light drinkers.
Results suggest that the heterogeneity of both alcohol use and psychiatric diagnosis are
important predictors of treatment out comes in adults with co-occurring disorders. While a
number of frameworks for conceptualizing heterogeneity of substance use and psychiatric
disorders have been proposed (McGovern et al. 2007; Ries 1993), our findings suggest that
simple tools, such as urine tests for EtG and psychiatric diagnosis, can be used to identify
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who is likely to respond to TAU and CM. The implications from this study in addition to
findings from our other study (Oluwoye et al., Under Review) examining the differences in
treatment outcomes among individuals with stimulant use disorders and various SMIs (i.e.,
schizophrenia, bipolar, and major depressive disorders) suggest that personalized treatment
approaches should be tailored to specific SMI diagnosis and substance use severity among
adults with co-occurring disorders.
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The relatively small sample size of this study, particularly when analyzing outcomes in the
CM group, resulted in small numbers of individuals in specific groups (e.g., light drinkers
with depression). Therefore, it is possible that outliers may have influenced results.
Participant recruitment from one treatment facility may also limit the generalizability of
study findings. Replication of our findings in a larger sample recruited across multiple
agencies is needed. While it is possible that diagnostic errors could have occurred, we used a
structured diagnostic interview and other procedures including the use of trained research
staff to assure accuracy of diagnosis.

Conclusions
Findings provide initial evidence that the interaction between drinking severity and
psychiatric diagnosis, rather than the effect of each of these variables in isolation, is
important when predicting alcohol treatment response in those who suffer from co-occurring
disorders. If validated in larger samples, this finding may have important implications for
improving outcomes of heavy drinkers, especially those who suffer from co-occurring major
depression.
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Fig. 1.

Mean percentage of ethyl glucuronide (EtG)-positive urine samples during treatment across
heavy and light drinkers and serious mental illness diagnoses (N = 79). Note: EtG, ethyl
glucuronide; significance of main effects: pre-treatment drinking severity (p = 0.001) and
SMI diagnosis (p = 0.022)
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